利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.01 秒)

    Bacterial DNA as Markers of Cardiovascular and/or Metabolic Disease
    2.
    发明申请
    Bacterial DNA as Markers of Cardiovascular and/or Metabolic Disease 审中-公开
    细菌DNA作为心血管和/或代谢疾病的标记物

    公开(公告)号：US20120021421A1

    公开(公告)日：2012-01-26

    申请号：US13201307

    申请日：2010-02-12

    申请人： Jacques Amar ,  Remy Burcelin ,  Chantal Chabo

    发明人： Jacques Amar ,  Remy Burcelin ,  Chantal Chabo

    IPC分类号： C12Q1/68 ,  C07H21/04

    CPC分类号： C12Q1/6888 ,  C12Q1/6883 ,  C12Q2600/136

    摘要： The present invention relates to an in vitro method for predicting and/or diagnosing a cardiovascular and/or metabolic disease in a subject, which method comprises determining the concentration of bacterial DNA in a biological sample of said subject, together with degenerated primers for predicting and/or diagnosing a cardiovascular and/or metabolic disease in a subject.

    摘要翻译： 本发明涉及用于预测和/或诊断受试者心血管和/或代谢疾病的体外方法，该方法包括测定所述受试者的生物样品中细菌DNA的浓度，以及用于预测和 /或诊断受试者的心血管和/或代谢疾病。

    New Uses of Lactic Acid Bacteria and Bifidobacteria
    3.
    发明申请
    New Uses of Lactic Acid Bacteria and Bifidobacteria 审中-公开
    乳酸菌和双歧杆菌的新用途

    公开(公告)号：US20110189149A1

    公开(公告)日：2011-08-04

    申请号：US12999555

    申请日：2008-06-20

    申请人： Remy Burcelin ,  Didier Carcano ,  Pierre Desreumaux ,  Sampo Lahtinen

    发明人： Remy Burcelin ,  Didier Carcano ,  Pierre Desreumaux ,  Sampo Lahtinen

    IPC分类号： A61K35/74 ,  A61P3/00 ,  A61P9/00 ,  A61P29/00

    CPC分类号： A61K35/74 ,  A61K35/744 ,  A61K35/745 ,  A61K35/747

    摘要： The invention comprises use of a bacterium selected from a lactic acid bacterium, a Bifidobacterium and a mixture of any thereof in the manufacture of a food product, dietary supplement or medicament for lowering tissue inflammation (in particular, adipose, liver or muscle tissue inflammation) and treating cardiovascular disease in a mammal. The lactic acid bacteria and/or Bifidobacteria can also be used to treat diabetes and insulin resistance and induce enhanced secretion of insulin upon a glucose challenge and lower blood glucose levels without a concomitant decrease in weight gain.

    摘要翻译： 本发明包括使用选自乳酸菌，双歧杆菌及其混合物的细菌在制备食品，膳食补充剂或用于降低组织炎症（特别是脂肪，肝脏或肌肉组织炎症）的药物中的用途， 并治疗哺乳动物的心血管疾病。 乳酸菌和/或双歧杆菌也可用于治疗糖尿病和胰岛素抵抗，并且在葡萄糖激发时诱导增加胰岛素分泌并降低血糖水平，而不伴随体重增加的降低。

    METHOD FOR PREDICTING INSULINOPENIC TYPE 2 DIABETES
    4.
    发明申请
    METHOD FOR PREDICTING INSULINOPENIC TYPE 2 DIABETES 审中-公开
    胰岛素2型糖尿病预防方法

    公开(公告)号：US20140186829A1

    公开(公告)日：2014-07-03

    申请号：US14008631

    申请日：2012-04-02

    申请人： Remy Burcelin ,  Jacques Amar ,  Beverly Balkau

    发明人： Remy Burcelin ,  Jacques Amar ,  Beverly Balkau

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/689

    摘要： The present invention relates to an in vitro method, for predicting a risk of onset of type 2 diabetes in a subject, which method comprises the steps of: a) measuring the concentration of bacterial 16S rDNA in a biological sample of said subject; and b) comparing said measured concentration of bacterial 16S rDNA to a threshold level; wherein a measured concentration of bacterial 16S rDNA higher than the threshold level is indicative of an increased risk of onset of type 2 diabetes in the subject, and a measured concentration of bacterial 16S rDNA lower than the threshold level is indicative of a decreased risk of onset of type 2 diabetes in the subject.

    摘要翻译： 本发明涉及用于预测受试者的2型糖尿病发病风险的体外方法，该方法包括以下步骤：a）测量所述受试者生物样品中细菌16S rDNA的浓度; 和b）将所述测量的细菌16S rDNA浓度与阈值水平进行比较; 其中测量的高于阈值水平的细菌16S rDNA的浓度指示受试者中2型糖尿病发病的风险增加，并且测定的低于阈值水平的细菌16S rDNA的浓度表明发病风险降低 的2型糖尿病。